| Literature DB >> 29311880 |
Eva M Bauch1,2, Christina Andreou3, Vanessa H Rausch1,4, Nico Bunzeck1,5.
Abstract
In constantly changing environments, it is crucial to adaptively respond to threatening events. In particular, painful stimuli are not only processed in terms of their absolute intensity, but also with respect to their context. While contextual pain processing can simply entail the repeated processing of information (i.e., habituation), it can, in a more complex form, be expressed through predictions of magnitude before the delivery of nociceptive information (i.e., adaptive coding). Here, we investigated the brain regions involved in the adaptation to nociceptive electrical stimulation as well as their link to dopaminergic neurotransmission (placebo/haloperidol). The main finding is that haloperidol changed the habituation to the absolute pain intensity over time. More precisely, in the placebo condition, activity in left postcentral gyrus and midcingulate cortex increased linearly with pain intensity only in the beginning of the experiment and subsequently habituated. In contrast, when the dopaminergic system was blocked by haloperidol, a linear increase with pain intensity was present throughout the entire experiment. Finally, there were no adaptive coding effects in any brain regions. Together, our findings provide novel insights into the nature of pain processing by suggesting that dopaminergic neurotransmission plays a specific role for the habituation to painful stimuli over time.Entities:
Keywords: EEG; habituation; haloperidol; pain; pharmacological fMRI
Year: 2017 PMID: 29311880 PMCID: PMC5742644 DOI: 10.3389/fnhum.2017.00630
Source DB: PubMed Journal: Front Hum Neurosci ISSN: 1662-5161 Impact factor: 3.169
Figure 1Experimental design. Participants underwent three phases. In the first and third phase (absolute task), electrical stimulation with three different magnitudes were presented randomly intermixed to the back of the hand. Subjects had to make low/medium/high judgments (see experimental procedures for details). In between both phases, participants took part in the adaptive task, where they learned the association between three contexts and three visual cues that predicted with 50% probability either: (1) a high or a medium stimulation; (2) a medium or a low stimulation; or (3) a high or a low stimulation. Participants made a relative low/high judgment (see experimental procedures for details).
Likert ratings for potential side effects (1 = no side effects; 7 = extreme side effects) before, during and after the fMRI experiment in the placebo and haloperidol condition (n = 20).
| Treatment | 1st assessment (before DI) | 2nd assessment (2.5 h after DI) | 3rd assessment (4.5 h after DI) |
|---|---|---|---|
| Placebo | 1.54 (0.46) | 1.43 (0.30) | 1.44 (0.39) |
| Haloperidol | 1.54 (0.44) | 1.41 (0.39) | 1.53 (0.42) |
Values represent mean ratings across-subject means (SD). DI, drug intake.
Reaction times (RTs) of hits in the absolute task for the first and third phase (n = 20).
| Drug | Phase | Stimulation magnitude | ||
|---|---|---|---|---|
| Low | Medium | High | ||
| Placebo | I | 1115 (193) | 1384 (192) | 1259 (180) |
| III | 1119 (206) | 1373 (293) | 1191 (168) | |
| Haloperidol | I | 1111 (301) | 1465 (227) | 1241 (377) |
| III | 1135 (172) | 1390 (210) | 1268 (257) | |
Values represent RTs of correct responses across-subject means in ms (SD).
Proportion of hits in the absolute task for the first and third phase (n = 20).
| Drug | Phase | Stimulation magnitude | ||
|---|---|---|---|---|
| Low | Medium | High | ||
| Placebo | I | 0.83 (0.11) | 0.70 (0.14) | 0.72 (0.21) |
| III | 0.76 (0.19) | 0.74 (0.19) | 0.77 (0.19) | |
| Haloperidol | I | 0.74 (0.24) | 0.66 (0.15) | 0.64 (0.22) |
| III | 0.76 (0.16) | 0.75 (0.14) | 0.68 (0.12) | |
Values represent proportions of correct responses across-subject means (SD).
RTs of hits in the adaptive task (n = 20).
| Drug | Context | Relative stimulation magnitude | |
|---|---|---|---|
| Low | High | ||
| Placebo | 1 (med/high) | 1276 (243) | 1272 (272) |
| 2 (low/med) | 1104 (145) | 1447 (212) | |
| 3 (low/high) | 1041 (161) | 1119 (186) | |
| Haloperidol | 1 (med/high) | 1377 (243) | 1289 (267) |
| 2 (low/med) | 1127 (147) | 1489 (254) | |
| 3 (low/high) | 1070 (219) | 1158 (221) | |
Values represent RTs of correct responses across-subject means in ms (SD).
Proportion of hits in the adaptive task (n = 20).
| Drug | Context | Relative stimulation magnitude | |
|---|---|---|---|
| Low | High | ||
| Placebo | 1 (med/high) | 0.90 (0.09) | 0.87 (0.12) |
| 2 (low/med) | 0.86 (0.12) | 0.78 (0.18) | |
| 3 (low/high) | 0.96 (0.06) | 0.96 (0.08) | |
| Haloperidol | 1 (med/high) | 0.86 (0.12) | 0.87 (0.10) |
| 2 (low/med) | 0.87 (0.10) | 0.75 (0.17) | |
| 3 (low/high) | 0.93 (0.10) | 0.93 (0.08) | |
Values represent proportions of correct responses across-subject means (SD).
Figure 2Main effect of electrical stimulation in the absolute task (A) and adaptive task (B). The highlighted voxels exhibited increased BOLD activity during noxious stimulation p < 0.001, family-wise error (FWE)-corrected at cluster level. Maps of activations are superimposed on a T1 group template. Note that both tasks require different cognitive demands; therefore, both main effects are not formally compared.
Figure 3fMRI results in the absolute task. Analyses revealed a significant interaction between stimulation magnitude, drug and time in left postcentral gyrus (A) and left midcingulate cortex (B). Under placebo in phase I, activity increased as a function of stimulation magnitude (absolute coding), and this effect was absent in phase III (i.e., habituation). Under haloperidol, however, there was no significant habituation from phase I to phase III. The significant interaction effects are highlighted by the asterisk. Maps of activations are superimposed on a T1 group template. Error-bars denote one standard error of the mean.